Today: 8 June 2026
Browse Category

NYSE:ABBV 11 January 2026 - 27 January 2026

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
1 2 3 4 5

Stock Market Today

  • Netflix Shares Rise as Founder Reed Hastings Exits Board, Jay Hoag Takes Chair
    June 8, 2026, 11:29 AM EDT. Netflix Inc. (NFLX) shares rose about 1% on Friday, defying a broader market pullback, following co-founder Reed Hastings' formal exit from the board. Hastings, who co-founded Netflix in 1997 and served as CEO for over 25 years, stepped down as executive chairman, with longtime independent director Jay Hoag appointed as new Chairman. Hastings' departure marks the end of nearly three decades leading Netflix's transformation from a DVD rental service to a streaming giant. Retail investor sentiment on NFLX shifted from bearish to extremely bullish, with 74% of analysts rating the stock as Buy or Hold and an average 12-month price target of $114.56, implying a 39% upside from current levels.

Latest articles

Dow Jones gains with chip stocks ahead of inflation data

Dow Jones gains with chip stocks ahead of inflation data

8 June 2026
Chip stocks surged, powering the Nasdaq up 1.72% and the S&P 500 1.09% higher, while the Dow rose 0.48% to 51,110 as investors bought back Friday’s losses after a strong jobs report fueled Fed-rate worries; May CPI inflation data Wednesday and oil prices remain key risks for market direction.
Growth ETFs Draw Attention Again as Investors Eye Big Tech Weighting

Growth ETFs Draw Attention Again as Investors Eye Big Tech Weighting

8 June 2026
Invesco QQQ Trust surged 2.2% and Vanguard growth ETFs gained over 1% as tech stocks rebounded, spotlighting growth ETFs’ outperformance—VUG returned 15.42% annually over five years, beating VOO—amid record $7.43 billion U.S. equity fund inflows driven by AI-led rallies, but concentrated tech bets mean higher volatility if sentiment shifts, especially with inflation and Fed risks looming.
Alphabet’s $80 billion AI stock sale puts Google’s rally to the test

Alphabet AI Search Drives Wall Street Target Hikes, Cloud Margins Still Draw Scrutiny

8 June 2026
Alphabet has ordered over 3 million TPUs from Intel for 2028 as it ramps up AI infrastructure, prompting Piper Sandler to raise its price target to $445 on rapid AI-assisted search growth, while UBS warns faster Google Cloud TPU revenue could pressure margins; Alphabet shares recently traded at $362.21, down $6.32, after boosting its equity offering to $84.75 billion to finance the AI buildout.
$95 Billion Dividend ETF May Not Be As Safe As It Looks

$95 Billion Dividend ETF May Not Be As Safe As It Looks

8 June 2026
SCHD’s top 10 holdings now make up about 43.5% of assets, raising concentration risk just as investors pile in for safety after a tech-led selloff; with $95.17 billion in assets, a 3.24% yield, and a 0.06% expense ratio, SCHD traded up 0.4% to $32.44 Monday, but its performance and risk profile now hinge more than ever on a handful of big stocks.
Wall Street’s Chip Rebound Lifts Nasdaq — Inflation Test Comes Next

Wall Street’s Chip Rebound Lifts Nasdaq — Inflation Test Comes Next

8 June 2026
Intel soared 8.5% to lead a 4.6% surge in chip stocks after reports Alphabet tapped it to make 3 million in-house chips and Nvidia was evaluating its technology, powering a 1.43% Nasdaq jump as investors returned to AI trades ahead of Wednesday’s key inflation data; Citigroup raised its S&P 500 target to 8,100, but Goldman Sachs warned the Fed may keep rates unchanged through 2026.
Go toTop